信隆健康(002105) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥215,590,965.89, a decrease of 48.05% compared to the same period last year[4]. - The net profit attributable to shareholders was a loss of ¥9,044,770.05, representing a decline of 114.39% year-on-year[4]. - The net profit after deducting non-recurring gains and losses was a loss of ¥12,481,844.87, down 122.76% from the previous year[4]. - The company experienced a 90.94% decline in net profit for the first nine months of 2023, totaling ¥18,658,147.09[9]. - Total operating revenue for the current period is ¥739,166,037.27, a decrease of 49.9% compared to ¥1,470,016,977.28 in the previous period[17]. - Net profit for the current period is ¥18,658,147.09, a significant decline of 90.9% from ¥205,890,796.80 in the previous period[18]. - Total comprehensive income for the current period is ¥11,440,917.02, a decrease of 94.7% from ¥214,604,444.06 in the previous period[19]. - Basic and diluted earnings per share for the current period are both ¥0.061, compared to ¥0.516 in the previous period[19]. Assets and Liabilities - Total assets at the end of Q3 2023 were ¥1,704,444,531.00, a decrease of 11.05% from the end of the previous year[4]. - As of September 30, 2023, the company's total assets amounted to RMB 1,704,444,531, a decrease from RMB 1,916,185,931.79 at the beginning of the year[16]. - Total current liabilities decreased to RMB 547,867,381.77 from RMB 733,523,115.19, a reduction of about 25.3%[16]. - The company's total liabilities decreased to RMB 648,174,722.27 from RMB 843,848,394.70, reflecting a decline of approximately 23.1%[16]. - The equity attributable to shareholders of the parent company decreased to RMB 944,537,726.60 from RMB 962,688,153.89, a decrease of about 1.9%[16]. Cash Flow and Investments - The company's cash flow from operating activities for the year-to-date was ¥210,777,103.89, an increase of 2.10%[9]. - Cash flow from operating activities for the current period is ¥210,777,103.89, slightly up from ¥206,448,259.93 in the previous period[20]. - The company reported a net cash outflow from investing activities of ¥29,379,717.03, compared to a net outflow of ¥40,723,436.96 in the previous period[21]. - The company's cash and cash equivalents increased by 248.05% to ¥40,552,954.67, primarily due to increased cash flow from financing activities[9]. - Cash and cash equivalents at the end of the period amount to ¥546,114,803.97, an increase from ¥431,808,546.64 at the end of the previous period[21]. Accounts Receivable and Inventory - The company reported a significant reduction in accounts receivable by 40.26% due to a sharp decline in market demand and orders[8]. - Accounts receivable decreased significantly to RMB 222,157,454.73 from RMB 371,864,562.22, representing a decline of about 40.3%[15]. - Inventory decreased by 34.72% as a result of reduced production volume due to lower market demand[8]. - Inventory levels dropped to RMB 197,906,481.90 from RMB 303,181,416.83, indicating a reduction of approximately 34.8%[15]. Research and Development - Research and development expenses for the year-to-date were ¥34,001,446.87, down 22.67% compared to the same period last year[9]. - Research and development expenses for the current period are ¥34,001,446.87, down 22.5% from ¥43,969,187.88 in the previous period[18]. Other Information - The third quarter report has not been audited[22]. - The company has implemented new accounting standards starting from 2023[22]. - The financial statement adjustments related to the first-time implementation of new accounting standards are applicable[22]. - The board of directors announced the third quarter report on October 26, 2023[22]. - There are no specific performance summaries or user data provided in the document[22]. - Future outlook and performance guidance are not detailed in the document[22]. - Information regarding new product and technology development is not mentioned[22]. - Market expansion and mergers or acquisitions are not discussed in the document[22]. - Other new strategies are not outlined in the content[22]. - The document does not provide specific financial figures or percentages[22].